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A large percentage of patients on extracorporeal membrane
oxygenation (ECMO) require continuous renal replacement
therapy (CRRT) usually performed through a different venous
access or by introducing a filter into the ECMO circuit. Here,
we evaluated the efficacy and safety of including a CRRT
machine in the circuit by connecting its inlet line after the
centrifugal pump and its outlet line before the oxygenator.
We tested the function of the combined system initially in a
closed circuit, followed by an experimental animal study, and,
finally, in a clinical trial with six children. Both machines
functioned adequately and there were no significant changes
in the pressures of the ECMO circuit after the introduction of
the CRRT device, thus achieving the preset negative balances
and normalization of the serum urea and creatinine
concentrations. The mean life of the filters was about 138h,
and only one filter needed changing due to clotting. Our
study shows that the introduction of a CRRT device into the
ECMO circuit is a safe and effective technique that improves
fluid balance, increases filter life, and does not cause
complications. For these reasons, this may be a good method
for performing CRRT in patients on ECMO.
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Extracorporeal membrane oxygenation (ECMO) is used for
cardiac and/or respiratory support in patients in whom other
measures have failed. When using this technique, up to 50%
of patients require continuous renal replacement therapy
(CRRT).1 Renal failure, hypervolemia, and edema are
frequent in patients on ECMO.2
There are a number of methods for performing CRRT
during ECMO. The most widely used is to introduce a
hemofiltration filter into the ECMO circuit and to control
the ultrafiltrate volume using an intravenous infusion pump.
Another possibility is to perform renal replacement therapy
through a venous access independent from the ECMO
circuit. It is also possible to include a CRRT machine in the
ECMO circuit. It has been in use in several ECMO
departments and has been published as a single case,3 but
there are no studies that have analyzed the efficacy of this
possibility. The objective of the present study has been to test
the efficacy and safety of the inclusion of a CRRTmachine in
the ECMO circuit.
RESULTS
Closed circuit
The results are summarized in Table 1. Both machines
functioned correctly and there were no significant changes in
the pressures in the ECMO circuit. Initially, the Prisma device
(Hospal, Spain) detected that the inlet pressure was positive
and triggered the ‘arterial line disconnection’ alarm. How-
ever, this machine allows the alarm to be silenced, and the
system continued functioning normally, achieving the preset
negative balances.
Experimental animal study
The ECMO and CRRT parameters used, and the pressures
and flows obtained are shown in Table 1. The system was
used for 2 h with no incidences.
Clinical study
Of the 23 patients treated using ECMO in our pediatric
intensive care unit, 19 required CRRT. In two cases, the HF
filter was introduced into the circuit, in 11, CRRT was
performed through an independent venous access, and in six,
the CRRT machine was connected to the ECMO circuit.
http://www.kidney-international.org techn i ca l no tes
& 2009 International Society of Nephrology
Received 17 May 2009; revised 22 July 2009; accepted 25 August 2009;
published online 30 September 2009
Correspondence: Jesu´s Lo´pez-Herce, Cid. Unidad de Cuidados Intensivos
Pedia´tricos, Hospital General Universitario Gregorio Maran˜o´n, Dr Castelo 47,
28009 Madrid, Spain. E-mail: pielvi@ya.com
Kidney International (2009) 76, 1289–1292 1289
These six patients aged between 3 days and 8 years, with body
weights between 2.3 and 23 kg, were included in the study.
The data, including number of filters used, mean life of the
filters, heparinization, negative balances, and initial and final
urea and creatinine concentrations, are shown in Table 2. The
indication for CRRT was renal failure and/or hypervolemia.
Both the ECMO and the CRRT functioned correctly in all
cases, accurately achieving the preset negative balances, and
with normalization of the urea and creatinine concentrations.
There were no changes in the pressures in the ECMO circuit
before or after inclusion of the CRRT machine. The entry
pressure of the CRRT circuit was negative in only one patient;
in the remainder, the pressure was positive, though this did
not affect the functioning of the system. The patients
tolerated the technique well, with no evidence of hypotension
or other adverse effects. The mean life of the filters was
138.4 h (range, 37–271 h) (Table 2). In four patients, the same
CRRT filter was used throughout the duration of ECMO.
Only one filter had to be changed because of clotting. The
rest of the filter changes were performed routinely because
the patient had to be transferred to hemodynamic study.
DISCUSSION
According to the Extracorporeal Life Support Organization,2
36% of patients on ECMO require CRRT, and this has
reached 50% in other series.1 Acute renal failure occurs in
50% of patients on ECMO.4,5 The management of renal
dysfunction and hypervolemia using CRRT in patients
on ECMO improves fluid balance, resolves electrolyte
imbalances, helps to improve calorie delivery by eliminating
the need for fluid restriction, and reduces diuretic require-
ments.6 In addition, the possibility for withdrawal of
extracorporeal assistance is linked to the reduction of
edema.4,5
There are advantages and drawbacks to each of the three
methods for performing CRRT in patients on ECMO. At first
sight, it would appear simplest to perform CRRT through a
venous access independent from the ECMO circuit. However,
if the patient has not previously required CRRT, canalization
of a new central venous line with a large-caliber catheter after
starting ECMO is complicated, and anticoagulation increases
the risks.
The introduction of a hemofiltration filter into the ECMO
circuit without a ‘in-line’ CRRT machine is the most widely
used. The filter inlet is connected after the ECMO pump and
the outlet is connected once again to the ECMO circuit; in
circuits with a reservoir, the blood is usually returned to the
reservoir (Figure 1). The effluent volume is controlled by an
intravenous infusion pump included in the ultrafiltrate line,
and this must be measured hourly. This technique has the
advantage of being relatively simple and cheap.1,6 However,
there is no control over the blood flow through the hemofilter
and intravenous infusion pumps are not accurate when used
to slow down the passage of high-pressure ultrafiltrate fluid.7
We used a 0.3 m2 filter (Renaflow, Minntech, Minneapolis,
USA) introduced into the ECMO circuit in two patients. The
ultrafiltrate volume was controlled using intravenous infu-
sion pumps (IVAC model 560, Alaris-Cardinal, San Diego,
USA), detecting a large discrepancy between the preset
ultrafiltrate volume and the volume obtained, due to the
inability of the intravenous infusion pump to hold back the
filtration sufficiently; this led to the need for very strict
control by the nursing staff. Another drawback is that there is
no monitoring of the pressures in the hemofiltration circuit,
and clotting or rupture of the filter cannot be detected early.
For these reasons, some authors propose filter changes at
preset times,1 although changes can lead to complications
due to the need to manipulate the circuit.
Table 1 | ECMO and CRRT variables in the closed circuit (in vitro) and in the experimental animal (in vivo) at different ECMO
flows
In vitro In vivo
Study Low-flow ECMO High-flow ECMO Minimal assistance Maximal assistance
ECMO
Blood flow (l/min) 0.45–0.6 1–2.36 0.65 0.8
Preoxygenator pressure 90–92 87–144 166–168 160–176
Postoxygenator pressure 71–75 85–129 167–157 155–172
Suction pressure 19–22 18–21 15 to 24 23 to 26
CRRT
Blood flow (ml/min) 40–180 90–180 40–100 40–160
Ultrafiltrate flow (ml/h) 100 100–300 0 0
Replacement flow (ml/h) 100–350 100–1000 150–300 150–1000
Dialysate flow (ml/h) 0 1000 600 600–1000
Inlet pressure 70–25 88–20 139–175 107–170
Outlet pressure 68–157 105–213 175–200 175–236
Filter pressure 66–203 115–261 185–230 180–300
Transmembrane pressure 0–11 0–60 21–33 17–49
Filter pressure drop 0–45 13–51 31–6 60–4
Effluent pressure 50 50 50 50
CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation.
Pressure is measured in mm Hg.
The pressures remained stable in the ECMO circuit throughout the experiment, and were not affected by the inclusion of CRRT. The inlet pressure to the hemofilter may be
seen to be positive.
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The possibility of including a venovenous CRRT machine
in the ECMO circuit was proposed as a possible solution for
these problems.8 Our study is the first to have analyzed the
function of a CRRTmachine in an ECMO circuit in vitro, in
an animal model, and, finally, in children. The CRRT and
ECMO functioned correctly, without complications, in all
three phases of the study.
In our experience, the inclusion of a renal filtration device
in the ECMO circuit improves the monitoring of filter
function and the accuracy of fluid balance. It has been
reported that in some patients the real fluid removed by
Prisma monitor was different from what was reported by the
machine. The amount of variance was significant in some
cases (relative to small size of the patient). For this reason,
it could be necessary to measure the real fluid removed to
make sure the accuracy of fluid balance.
The blood flow in the CRRTmachine is high and constant,
avoiding alarms being triggered due to difficulty of blood
extraction or return. In addition, CRRT can be withdrawn in
a controlled manner, without affecting ECMO function, if the
patient has to be transferred to hemodynamics or if clotting
of the filter occurs.
Owing to the stability of the system, the absence of
problems of blood entry and return, and the dose of heparin
received, filter life (138.4 h) was significantly longer than
when CRRT is performed through an independent venous
Table 2 | Patient data
Patient number 1 2a 2a 3 4 5 6
Age (months) 6 96 96 3 0.1 24 7
Weight 7 23 23 6 2.9 9 7
Diagnosis HLVS Glenn
Surgery
HLVS Fontan
Surgery
Heart
transplant
Dilated
cardiomyopathy
HLVS Norwood
Surgery
Dilated
cardiomyopathy
Heart
transplant
Indication Hyper-
volemia
ARF ARF Hyper-
volemia
Hyper-
volemia
Hyper-
volemia
ARF+
hypervolemia
Technique CVVHF CVVHDF CVVHDF CVVHF CVVHF CVVHF CVVHDF
Filters 0.6 m2 0.9 m2 0.9 m2 0.6 m2 0.6 m2 0.6 m2 0.6 m2
Number of filters 1 2 1 2 1 1 3
Mean of filters life 37 116 271 99 69 186 191
Heparin in CRRT+ECMO (U/kg/h) 5+24 5+14 5+20 5+18 5+10 5+18 5+3
CRRT
Blood flow (ml/min) 40 90 90 50 40 60 40
Ultrafiltrate flow (ml/h) 15 110 80 30 30 50 30
Replacement fluid flow (ml/h) 200 500 500 150 150 200 100
Dialysate flow (ml/h) 0 950 1000 0 0 0 300
Inlet pressure (mm Hg) 10 102 50 45 130 98 137
Outlet pressure (mm Hg) 126 197 254 97 153 153 156
Filter pressure (mm Hg) 142 252 297 116 160 182 170
Filter pressure drop (mm Hg) 18 53 37 20 12 31 12
Transmembrane pressure (mm Hg) 39 111 52 25 24 27 32
Effluent pressure (mm Hg) 450 450 450 450 450 450 450
Total negative balance (ml) 566 22,819 32,302 9671 2161 8834 11,232
Initial creatinine (mg/dl) 0.41 0.84 0.6 0.25 0.67 0.45 0.36
Final creatinine (mg/dl) 0.19 0.78 0.59 0.32 0.2 0.36 0.2
Initial urea (mg/dl) 20 52 42 47 36 36 32
Final urea (mg/dl) 10 45 52 44 15 50 18
ECMO
Before inclusion of CRRT
Blood flow (l/min) 0.54 1.8 1.9 0.96 0.42 0.64 0.95
Revolutions (rpm) 2110 2515 2375 1730 2140 2240 2275
Premembrane pressure (mm Hg) 100 159 109 74 122 124 122
Postmembrane pressure
(mm Hg)
100 135 98 66 119 113 116
Suction pressure 9 0 16 6 2 9 6
After inclusion of CRRT
Blood flow (l/min) 0.51 1.8 1.9 0.96 0.41 0.64 0.94
Revolutions (rpm) 2110 2515 2375 1730 2140 2240 2275
Premembrane pressure (mm Hg) 109 166 122 80 122 123 124
Postmembrane pressure (mm Hg) 100 144 107 72 117 114 118
Suction pressure 9 1 21 1 3 10 6
ARF, acute renal failure; CRRT, continuous renal replacement therapy; CVVHDF, continuous veno-venous hemodiafiltration; CVVHF, continuous veno-venous hemofiltration;
ECMO, extracorporeal membrane oxygenation; HLVS, hypoplastic left ventricle syndrome.
aPatient 2 was analyzed before and after heart transplant.
Flows and pressures are represented by mean values.
Kidney International (2009) 76, 1289–1292 1291
MJ Santiago et al.: ECMO and CRRT techn i ca l no tes
access (36.8 h).9 Furthermore, the presence of accurate
monitoring systems for circuit pressures and ultrafiltrate
volume improves the control and safety of the patient, and
reduces nursing workload. The theoretical drawbacks to this
technique are that it adds complexity to the circuit and can
increase costs.6
We conclude that the inclusion of a CRRT device in
the ECMO circuit is a safe and effective technique that
improves fluid balance control, increases filter life, and does
not lead to complications. For these reasons, it may be
considered a good method for performing CRRT in patients
on ECMO.
MATERIALS AND METHODS
The ECMO circuit used was a heparin-coated, closed circuit with no
venous reservoir, and composed of a centrifugal pump (Jostra
Rotaflow HL20, Maquet, Rastatt, Germany) and hollow fiber
oxygenator (Quadrox, Jostra, Maquet, Rastatt, Germany). The total
priming volume was 450ml. CRRTwas performed using the Prisma
machine with polyacrylonitrile (AN69) membrane filters, with
surface areas of 0.6m2 and 0.9m2 and total priming volumes of the
circuits of 100ml and 120ml, respectively.
Connection of the CRRT device into the ECMO circuit was
performed in the following manner: the inlet (arterial) line of the
CRRT circuit was connected after the centrifugal pump by a three-
way tap that was also used for the infusion of heparin, and the outlet
(venous) line was connected to the circuit at another tap before the
oxygenator (Figure 2).
The study was performed in three phases. First, the function of
the two devices was tested in a closed circuit primed using colloids.
We varied the ECMO blood flow and the CRRT parameters (flows
of blood, replacement fluid, and dialysis solution), recording the
pressures in the two devices. The system was then used in the
experimental surgery laboratory on a minipig of 7 kg body weight,
maintained with mechanical ventilation, propofol, fentanyl, and
muscle relaxation with atracurium. The international guidelines for
the care of experimental animals were observed. The external jugular
vein and the carotid artery were catheterized with 12 F and 8 F
ECMO catheters. The femoral artery and vein were cannulated for
arterial blood pressure and central venous pressure monitorization,
and for extraction of blood samples. Finally, the technique was used
in six patients requiring ECMO, after obtaining informed consent
from the parents. Anticoagulation was performed with heparin,
always administering 5U/kg/h into the hemofiltration circuit and
the remainder (mean of 15.3U/kg/h) into the ECMO circuit to
maintain an activated coagulation time (Hemochron Jr II, ITC,
Edison, USA), between 180 and 220 s.
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Figure 1 | In-line inclusion of the filter in the extracorporeal
membrane oxygenation (ECMO) circuit.
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Figure 2 | Inclusion of the continuous renal replacement
therapy (CRRT) device in the extracorporeal membrane
oxygenation (ECMO) circuit.
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